Themis CEO: Chikungunya Vaccine Could Be Approved In Two Years
Themis Bioscience CEO says the biotech’s €40m Series D financing will fund pivotal trials for its lead vaccine candidate for chikungunya and advance its oncology franchise.
You may also be interested in...
Plans to have candidate vaccines ready for testing against infectious diseases during an evolving epidemic have taken a step forward with the announcement of a partnership between CEPI, the global fund supported by governments and philanthropists, and the vaccine-focused European biotech, Themis Bioscience.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.